|Company name||Immunomedics, Inc.|
NEW YORK, October 4, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Immunomedics, Inc. (NYSE: IMMU) on behalf of long-term stockholders of Immunomedics securities.
Bragar Eagel and Squire is investigating certain officers and directors of Immunomedics following a class action complaint that was filed against Immunomedics on December 27, 2018.
The complaint alleges that between August 23, 2018 and December 20, 2018, inclusive (the “Class Period”), defendants made false and/or misleading statements, as well as failed to disclose material adverse facts. As alleged in the Complaint, on December 17, 2018, FDAnews.com published an article titled “FDA Hits Immunomedics for Data Integrity Breach.” According to this article, “[t]he FDA cited Immunomedics for a host of violations – including its handling of a data integrity breach – observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” The article states that this breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.” Following this news, Immunomedics stock price dropped from $17.64 at close on December 19, 2018, to $14.17 at close on December 20, 2018.
If you are a long-term stockholder of Immunomedics securities, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.